NOW FDA APPROVED

The only FDA‑approved, evidence-based therapy for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.¹

Read the FDA Approval Press Release Learn More About Product Availability

Join Catalyst Pathways^™

A free, personalized program that offers patients and families one‐on‐one support through their treatment journey

Download Enrollment Form Visit Website

Get updates about FIRDAPSE

Sign up to stay informed with important news about FIRDAPSE.

NOTE: By providing this information you are only requesting more information about FIRDAPSE and are not signing up for Catalyst Pathways™.

All fields are required.

INDICATION AND IMPORTANT SAFETY INFORMATION

Expand

INDICATIONS AND USAGE:

FIRDAPSE is a potassium channel blocker indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.

CONTRAINDICATIONS

FIRDAPSE is contraindicated in patients with:

A history of seizures
Hypersensitivity to amifampridine phosphate or another aminopyridine

WARNINGS AND PRECAUTIONS

Seizures: FIRDAPSE can cause seizures. Consider discontinuation or dose-reduction of FIRDAPSE in patients who have a seizure while on treatment. FIRDAPSE is contraindicated in patients with a history of seizures.

Hypersensitivity: If a hypersensitivity reaction such as anaphylaxis occurs, FIRDAPSE should be discontinued and appropriate therapy initiated.

ADVERSE REACTIONS

The most common (> 10%) adverse reactions are: paresthesia, upper respiratory tract infection, abdominal pain, nausea, diarrhea, headache, elevated liver enzymes, back pain, hypertension, and muscle spasms.

To report SUSPECTED ADVERSE REACTIONS, contact Catalyst Pharmaceuticals at 1-844-347-3277 (1-844-FIRDAPSE) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Reference: 1. Full Prescribing Information for FIRDAPSE (amifampridine). Catalyst Pharma.; 2018